BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 33805714)

  • 1. Preclinical Investigation of Trifluoperazine as a Novel Therapeutic Agent for the Treatment of Pulmonary Arterial Hypertension.
    Grobs Y; Awada C; Lemay SE; Romanet C; Bourgeois A; Toro V; Nadeau V; Shimauchi K; Orcholski M; Breuils-Bonnet S; Tremblay E; Provencher S; Paulin R; Boucherat O; Bonnet S
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HMGB1 down-regulation mediates terameprocol vascular anti-proliferative effect in experimental pulmonary hypertension.
    Nogueira-Ferreira R; Ferreira-Pinto MJ; Silva AF; Vitorino R; Justino J; Costa R; Moreira-Gonçalves D; Quignard JF; Ducret T; Savineau JP; Leite-Moreira AF; Ferreira R; Henriques-Coelho T
    J Cell Physiol; 2017 Nov; 232(11):3128-3138. PubMed ID: 28036116
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis.
    McMurtry MS; Bonnet S; Wu X; Dyck JR; Haromy A; Hashimoto K; Michelakis ED
    Circ Res; 2004 Oct; 95(8):830-40. PubMed ID: 15375007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory effects of Prohibitin 1 on proliferation and apoptosis of pulmonary arterial smooth muscle cells in monocrotaline-induced PAH rats.
    Cao YY; Ba HX; Li Y; Tang SY; Luo ZQ; Li XH
    Life Sci; 2020 Jun; 250():117548. PubMed ID: 32173312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effects of dioscin on vascular remodeling in pulmonary arterial hypertension via adjusting GRB2/ERK/PI3K-AKT signal.
    Yang Y; Yin L; Zhu M; Song S; Sun C; Han X; Xu Y; Zhao Y; Qi Y; Xu L; Peng JY
    Biomed Pharmacother; 2021 Jan; 133():111056. PubMed ID: 33378960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-223 reverses experimental pulmonary arterial hypertension.
    Meloche J; Le Guen M; Potus F; Vinck J; Ranchoux B; Johnson I; Antigny F; Tremblay E; Breuils-Bonnet S; Perros F; Provencher S; Bonnet S
    Am J Physiol Cell Physiol; 2015 Sep; 309(6):C363-72. PubMed ID: 26084306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIM1 (Moloney Murine Leukemia Provirus Integration Site) Inhibition Decreases the Nonhomologous End-Joining DNA Damage Repair Signaling Pathway in Pulmonary Hypertension.
    Lampron MC; Vitry G; Nadeau V; Grobs Y; Paradis R; Samson N; Tremblay È; Boucherat O; Meloche J; Bonnet S; Provencher S; Potus F; Paulin R
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):783-801. PubMed ID: 31969012
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selenoprotein P Promotes the Development of Pulmonary Arterial Hypertension: Possible Novel Therapeutic Target.
    Kikuchi N; Satoh K; Kurosawa R; Yaoita N; Elias-Al-Mamun M; Siddique MAH; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Saito Y; Hoshikawa Y; Okada Y; Shimokawa H
    Circulation; 2018 Aug; 138(6):600-623. PubMed ID: 29636330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Calcineurin/NFAT Signaling Modulates Pulmonary Artery Smooth Muscle Cell Proliferation, Migration and Apoptosis in Monocrotaline-Induced Pulmonary Arterial Hypertension Rats.
    He RL; Wu ZJ; Liu XR; Gui LX; Wang RX; Lin MJ
    Cell Physiol Biochem; 2018; 49(1):172-189. PubMed ID: 30134231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of Celastramycin as a Novel Therapeutic Agent for Pulmonary Arterial Hypertension.
    Kurosawa R; Satoh K; Kikuchi N; Kikuchi H; Saigusa D; Al-Mamun ME; Siddique MAH; Omura J; Satoh T; Sunamura S; Nogi M; Numano K; Miyata S; Uruno A; Kano K; Matsumoto Y; Doi T; Aoki J; Oshima Y; Yamamoto M; Shimokawa H
    Circ Res; 2019 Jul; 125(3):309-327. PubMed ID: 31195886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Preclinical Validation of BET Inhibition for the Treatment of Pulmonary Arterial Hypertension.
    Van der Feen DE; Kurakula K; Tremblay E; Boucherat O; Bossers GPL; Szulcek R; Bourgeois A; Lampron MC; Habbout K; Martineau S; Paulin R; Kulikowski E; Jahagirdar R; Schalij I; Bogaard HJ; Bartelds B; Provencher S; Berger RMF; Bonnet S; Goumans MJ
    Am J Respir Crit Care Med; 2019 Oct; 200(7):910-920. PubMed ID: 31042405
    [No Abstract]   [Full Text] [Related]  

  • 13. Intratracheal Administration of Prostacyclin Analogue-incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension.
    Akagi S; Nakamura K; Matsubara H; Kondo M; Miura D; Matoba T; Egashira K; Ito H
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):290-8. PubMed ID: 26745002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiological roles of nuclear factor kappaB (NF-kB) in pulmonary arterial hypertension: effects of synthetic selective NF-kB inhibitor IMD-0354.
    Hosokawa S; Haraguchi G; Sasaki A; Arai H; Muto S; Itai A; Doi S; Mizutani S; Isobe M
    Cardiovasc Res; 2013 Jul; 99(1):35-43. PubMed ID: 23631839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Potential of Regorafenib-A Multikinase Inhibitor in Pulmonary Hypertension.
    Veeroju S; Kojonazarov B; Weiss A; Ghofrani HA; Weissmann N; Grimminger F; Seeger W; Novoyatleva T; Schermuly RT
    Int J Mol Sci; 2021 Feb; 22(3):. PubMed ID: 33540939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Emetine as a Therapeutic Agent for Pulmonary Arterial Hypertension: Novel Effects of an Old Drug.
    Siddique MAH; Satoh K; Kurosawa R; Kikuchi N; Elias-Al-Mamun M; Omura J; Satoh T; Nogi M; Sunamura S; Miyata S; Ueda H; Tokuyama H; Shimokawa H
    Arterioscler Thromb Vasc Biol; 2019 Nov; 39(11):2367-2385. PubMed ID: 31533472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.
    Bourgeois A; Lambert C; Habbout K; Ranchoux B; Paquet-Marceau S; Trinh I; Breuils-Bonnet S; Paradis R; Nadeau V; Paulin R; Provencher S; Bonnet S; Boucherat O
    J Mol Med (Berl); 2018 Feb; 96(2):223-235. PubMed ID: 29290032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icotinib Attenuates Monocrotaline-Induced Pulmonary Hypertension by Preventing Pulmonary Arterial Smooth Muscle Cell Dysfunction.
    Peng LY; Yu M; Yang MX; Liu P; Zhou H; Huang W; Kong H; Xie WP
    Am J Hypertens; 2020 Aug; 33(8):775-783. PubMed ID: 32301965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smad-dependent and smad-independent induction of id1 by prostacyclin analogues inhibits proliferation of pulmonary artery smooth muscle cells in vitro and in vivo.
    Yang J; Li X; Al-Lamki RS; Southwood M; Zhao J; Lever AM; Grimminger F; Schermuly RT; Morrell NW
    Circ Res; 2010 Jul; 107(2):252-62. PubMed ID: 20522807
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidized DNA Precursors Cleanup by NUDT1 Contributes to Vascular Remodeling in Pulmonary Arterial Hypertension.
    Vitry G; Paulin R; Grobs Y; Lampron MC; Shimauchi T; Lemay SE; Tremblay E; Habbout K; Awada C; Bourgeois A; Nadeau V; Paradis R; Breuils-Bonnet S; Roux-Dalvai F; Orcholski M; Potus F; Provencher S; Boucherat O; Bonnet S
    Am J Respir Crit Care Med; 2021 Mar; 203(5):614-627. PubMed ID: 33021405
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.